Celltrion Holds First R&D Event "Science & Innovation Day"

Current Status and Strategies for ADC New Drug Development
Accelerating the Transition to a New Drug Development Enterprise

Celltrion announced on the 25th that it held the "Celltrion Science & Innovation Day 2025" on the 22nd at the Fairmont Hotel in Yeouido, Seoul, targeting domestic and international pharmaceutical and biotech analysts.

This event, organized by Celltrion for the first time, was designed to share the company's achievements in new drug development, related strategies, and vision with professionals in the investment industry.

On the 22nd, at the Fairmont Hotel in Yeouido, Seoul, Kwon Kisung, Head of Research and Development at Celltrion, presented Celltrion's new drug development strategy during the "Celltrion Science & Innovation Day 2025." Celltrion

The main theme of the inaugural event was Antibody-Drug Conjugates (ADC). The program included a total of six individual sessions and a speaker panel session, covering topics such as Celltrion's new drug development strategy, Celltrion's biobetter ADC development strategy and current status, and PBX-7016-a new camptothecin payload (a cytotoxic anticancer agent) for next-generation ADC development. Through these sessions, the company introduced its technological direction and presented a detailed clinical roadmap.

Kwon Kisung, Head of Research and Development at Celltrion, delivered the first session, introducing Celltrion's new drug development strategy and mid- to long-term plans, emphasizing that the company is firmly establishing itself as a new drug development enterprise. He highlighted that, based on over 20 years of accumulated expertise in antibody research and production platforms, Celltrion is actively expanding its next-generation ADC pipeline and, when necessary, is securing promising technologies through proactive open innovation.

Lee Sooyoung, Head of New Drug Research at Celltrion, presented on ADC development strategies and current status, discussing the competitive landscape and differentiation strategies for each pipeline. She shared research achievements and development progress for key new drug pipelines, including 'CT-P70,' which is currently in Phase 1 clinical trials, as well as 'CT-P71' and 'CT-P73.' She cited each target's indications, patient population, and unmet medical needs as reasons for their high commercialization potential.

In addition to the three ADC pipelines highlighted that day, Celltrion also announced sequential development plans for "Bispecific ADCs," which can target two antigens, and "Dual-payload ADCs," which maximize therapeutic effects through payload combinations.

Yeo Norae, Senior Manager at Hyundai Motor Securities, who attended the event, said, "It was an opportunity to clearly understand Celltrion's new drug development strategy. I was able to get detailed explanations on areas that the market has been curious about, making it a valuable chance to confirm the direction of Celltrion's ADC new drug development."

The event also featured presentations from global ADC authority and ProfoundBio co-founder Dr. Tae Han, Jung Dooyoung, CEO of Pinobio, who is jointly developing with Celltrion, Jimmy Li, CEO of Wuxi XDC, and Cho Byungchul, Director of the Lung Cancer Center at Yonsei Severance, who is participating in the CT-P70 clinical trial. These presentations drew significant attention from both domestic and international analysts.

Seo Jinseok, CEO of Celltrion, stated, "In addition to Celltrion's extensive experience and know-how accumulated in the antibody field, we are accelerating new drug development through active collaboration. We will rapidly commercialize a variety of new drugs that can offer better therapeutic alternatives in areas with high unmet medical needs, including oncology."